All Stories

  1. Nucleotidomics: Extending Reversed-Phase Metabolomics to Untargeted Nucleotide Analysis
  2. Can the combination of 5-fluorouracil and gemcitabine increase the treatment efficacy of pancreatic and colon cancer?
  3. Protein Kinase Inhibitors as Regulators of ABC Transporters in Overcoming Cancer Multidrug Resistance: A Comprehensive Review of Recent Advances
  4. Evaluation of MTH1 and DCTPP1 inhibitors in fluorocyclopentenylcytosine (RX-3117) resistant lung cancer cells and potential cross resistance patterns
  5. The Role of the Ecto-Nucleotidases CD73 and CD39 in Chemo- and Immunotherapy
  6. Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines
  7. Obatoclax enhances TRAIL-induced apoptosis in non-small-cell-lung-cancer cells by increasing TRAIL receptor expression, priming for mitochondrial apoptosis and reducing XIAP levels
  8. Management of neurological symptoms in Lesch-Nyhan disease: A systematic review
  9. Corrigendum to “Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library” [Europ. J. Pharmacol. (2023) 938: 175395]
  10. The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity
  11. Obituary to Lynette Fairbanks, PhD
  12. Nucleo(s)tide metabolism as basis for drug development; the Anne Simmonds award lecture
  13. Effects of lactate dehydrogenase A and GLUT1 inhibition on human endothelial cell migration in relation to their intracellular nucleotide pool
  14. Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma
  15. Newly synthesized acridone derivatives targeting lung cancer: A toxicity and xenograft model study
  16. Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry
  17. Novel mass spectrometry-based assay for thymidylate synthase activity
  18. Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells
  19. Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
  20. G-Protein Signaling Modulator 2 as a Potential Biomarker in Colorectal Cancer: Integrative Analysis Using Genetic Profiling and Pan-Cancer Studies
  21. Pegylated nanoliposomal cisplatin ameliorates chemotherapy-induced peripheral neuropathy
  22. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer
  23. Exploring the role of oxidative stress and the effect of N‐acetylcysteine in thiopurine‐induced liver injury in inflammatory bowel disease: A randomized crossover pilot study
  24. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target
  25. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing
  26. Looking for the unexpected in purine and pyrimidine metabolism
  27. Extracellular vesicles: Emerging mediators of cell communication in gastrointestinal cancers exhibiting metabolic abnormalities
  28. Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism
  29. The Prognostic Value of ASPHD1 and ZBTB12 in Colorectal Cancer: A Machine Learning-Based Integrated Bioinformatics Approach
  30. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
  31. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
  32. Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
  33. The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance
  34. Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  35. Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  36. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  37. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  38. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  39. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  40. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  41. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  42. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  43. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  44. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  45. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  46. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  47. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  48. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  49. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  50. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  51. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  52. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  53. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  54. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library
  55. Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
  56. Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
  57. Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth
  58. Proceedings of the 19th International Symposium on purine and pyrimidine metabolism in man
  59. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo
  60. Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers
  61. A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships
  62. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment
  63. Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma
  64. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
  65. The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells
  66. Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy
  67. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells
  68. Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters
  69. New insights in research on purine and pyrimidine metabolism
  70. Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
  71. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
  72. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
  73. Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems
  74. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma
  75. A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
  76. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
  77. Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma
  78. Disrupters of the Thymidylate Synthase Homodimer Accelerate Its Proteasomal Degradation and Inhibit Cancer Growth.
  79. Disrupters of the Thymidylate Synthase Homodimer Accelerate Its Proteasomal Degradation and Inhibit Cancer Growth.
  80. Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro
  81. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
  82. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy
  83. The role of the microbiome in drug resistance in gastrointestinal cancers
  84. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
  85. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer
  86. 11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy
  87. Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
  88. New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma
  89. The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer
  90. Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models
  91. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase
  92. Resistance to differentiation affects ribo- and deoxyribonucleotide pools and sensitivity to pyrimidine metabolism antagonists in HL60 cells
  93. Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
  94. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
  95. NUC-1031 in biliary tract cancer: from bench to bedside and back?
  96. The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment
  97. Targeting telomerase for its advent in cancer therapeutics
  98. Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia
  99. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
  100. RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier
  101. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
  102. Recent updates on purine and pyrimidine metabolism in physiological and pathological settings
  103. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells
  104. The continuous rediscovery and the benefit–risk ratio of thioguanine, a comprehensive review
  105. Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
  106. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies
  107. Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
  108. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma
  109. CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
  110. The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies
  111. Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance
  112. Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?
  113. Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment
  114. Thiopurines with low-dose allopurinol (ThiLDA)—a prospective clinical one-way crossover trial
  115. Breastfeeding during R-CHOP chemotherapy: please abstain!
  116. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
  117. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
  118. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells
  119. From ‘Targeted Therapy’ to Targeted Therapy
  120. Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2
  121. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology
  122. Abstract 1267: Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)
  123. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer
  124. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine
  125. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
  126. Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
  127. E-drug delivery: a futuristic approach
  128. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation
  129. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment
  130. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases
  131. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
  132. DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.
  133. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor
  134. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
  135. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
  136. Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells
  137. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study
  138. WDR48 (WD repeat domain 48)
  139. Subcellular localization of several structurally different tyrosine kinase inhibitors
  140. Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited
  141. Abstract 5861: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1
  142. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma
  143. Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies
  144. Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.
  145. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.
  146. High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients
  147. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines
  148. Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks
  149. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
  150. The role of pharmacology in anticancer drug development
  151. Cancer drug resistance: a new perspective
  152. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
  153. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
  154. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
  155. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer
  156. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
  157. Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
  158. Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
  159. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
  160. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
  161. The potential of multi-compound nanoparticles to bypass drug resistance in cancer
  162. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
  163. Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?
  164. Resistance Mechanisms to AZD9291 and Rociletinib—Letter
  165. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer
  166. Abstract 1074: Combining forces: Synergy of erlotinib and crizotinib in a wild-type squamous non-small cell lung cancer cell line
  167. Abstract 4731: Phospho-akt: a potential resistance marker to chemotherapy and a therapy-target to restore sensitivity in pancreatic cancer
  168. Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
  169. Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate
  170. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
  171. Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring
  172. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
  173. A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.
  174. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.
  175. The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.
  176. Loont investeren in preventie?
  177. Erratum to: Glutamate and α-ketoglutarate: key players in glioma metabolism
  178. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
  179. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
  180. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?
  181. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
  182. Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
  183. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1
  184. The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines
  185. Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA
  186. Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil
  187. Advances in purine and pyrimidine metabolism in health and diseases
  188. hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
  189. Glutamate and α-ketoglutarate: key players in glioma metabolism
  190. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
  191. Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action
  192. ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors
  193. P2.09: cMET in NSCLC: Expression, Amplification and Mutations
  194. Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice
  195. The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2
  196. Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
  197. cMET Exon 14 Skipping: From the Structure to the Clinic
  198. Abstract 4725: Inhibition of DNA methyltransferase by RX-3117 (fluorocyclopentenylcytosine) leads to upregulation of hypomethylated targets
  199. Abstract 4336: Spliceosome inhibition as a novel therapeutic option in acute leukemia
  200. Abstract 332: Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma
  201. Abstract 2242: cMET in non-small cell lung cancer: pieces of the puzzle
  202. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).
  203. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Letter
  204. The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia
  205. Transport of six tyrosine kinase inhibitors: active or passive?
  206. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
  207. On the pharmacogenetics of non-small cell lung cancer treatment
  208. Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open
  209. Erratum
  210. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells
  211. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
  212. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  213. Precision medicine in cancer: beyond wishful thinking?
  214. Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
  215. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review
  216. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
  217. Role of Akt signaling in resistance to DNA-targeted therapy
  218. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis
  219. Contemporary reviews on cancer treatment
  220. Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma
  221. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance
  222. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR
  223. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies
  224. Abstract 2622: Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker
  225. Abstract 1624: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
  226. Abstract 572: Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
  227. Abstract 4335: Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed
  228. Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia
  229. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
  230. A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.
  231. Drug transport and metabolism of novel anticancer drugs
  232. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
  233. Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors
  234. Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future
  235. Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine
  236. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
  237. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival
  238. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters
  239. MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer
  240. Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer
  241. Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
  242. The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
  243. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
  244. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
  245. EZH2 (enhancer of zeste homolog 2 (Drosophila))
  246. Calcium/Magnesium Infusion for Oxaliplatin-Induced Neuropathy: Protective or Not?
  247. On the use of pharmacogenetics in cancer treatment and clinical trials
  248. Abstract 3134: Crizotinib inhibits tumor growth and metabolic inactivation of gemcitabine in new patient derived orthotopic pancreatic tumors with c-Met overexpression: A step toward personalized treatment in pancreatic cancer
  249. Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy
  250. AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients
  251. Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?
  252. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
  253. Design and Synthesis of Quinazolinone Tagged Acridones as Cytotoxic Agents and Their Effects on EGFR Tyrosine Kinase
  254. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells
  255. miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells
  256. Radiosensitization by Thymidine Phosphorylase Inhibitor in Thymidine Phosphorylase Negative and Overexpressing Bladder Cancer Cell Lines
  257. Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment
  258. Novel Developments in the Use of Antimetabolites
  259. Proceedings of the 15th International Symposium on Purine and Pyrimidine Metabolism in Man
  260. Novel Developments in Metabolic Disorders of Purine and Pyrimidine Metabolism and Therapeutic Applications of Their Analogs
  261. Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia
  262. USP1 (ubiquitin specific peptidase 1)
  263. A Polymorphism in the promoter is Associated with EZH2 Expression but not with Outcome in Advanced Pancreatic Cancer Patients
  264. Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)
  265. MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside
  266. Positioning of aminopeptidase inhibitors in next generation cancer therapy
  267. Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation
  268. Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
  269. MIR211 (microRNA 211)
  270. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study
  271. Abstract C82: Role of influx and efflux transporters on gut absorption of selected tyrosine kinase inhibitors in a polarized gut epithelium model system.
  272. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
  273. Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)
  274. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma
  275. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
  276. “One Marker Does Not Fit All”: Additional Translational and Validation Studies Are Needed to Identify Faithful Predictors of Pemetrexed Activity in Mesothelioma
  277. Gender, Cytidine Deaminase, and 5-Aza/Decitabine—Letter
  278. Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission Tomography
  279. Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression
  280. Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI
  281. Thymidylate synthase inhibitors for thoracic tumors
  282. Folates and antifolates in rheumatoid arthritis
  283. DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
  284. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
  285. Abstract 4628: Alterations in FPGS splicing as a plausible underlying mechanism of MTX resistance in ALL.
  286. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back
  287. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1
  288. Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?
  289. Chemosensitizing acridones: In vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies
  290. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
  291. Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure
  292. Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
  293. Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
  294. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
  295. Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells
  296. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
  297. Cancer therapeutics and research: novel developments
  298. Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer
  299. Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
  300. Role of E3 ubiquitin ligases in lung cancer
  301. EO9 (Apaziquone): from the clinic to the laboratory and back again
  302. TAS-102: more than an antimetabolite
  303. High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer
  304. 441 Quality Assurance of Biomarker Assays in Clinical Trials
  305. The use of capecitabine in daily practice: a study on adherence and patients' experiences
  306. Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
  307. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin
  308. Research Highlights: Highlights from the Latest Articles in Pharmacogenomics of Irinotecan/Cisplatin Toxicity
  309. EGF Receptor-Targeted Therapy in Non-Small-Cell Lung Cancer: Role of Germline Polymorphisms in Outcome and Toxicity
  310. Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
  311. Pharmacogenetics of Conventional Chemotherapy in Non-Small-Cell Lung Cancer: A Changing Landscape?
  312. Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
  313. Guidelines for the use and interpretation of assays for monitoring autophagy
  314. Abstract 186: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR211 in pancreatic cancer
  315. Abstract 1770: Metabolism and mechanism of action of fluorocyclopentenylcytosine (RX-3117)
  316. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine
  317. TFAP2E-DKK4and Chemoresistance in Colorectal Cancer
  318. EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group
  319. “The only thing I know is that I know nothing”: 5-fluorouracil in human milk
  320. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
  321. Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients wi...
  322. TFAP2E–DKK4 and Chemoresistance in Colorectal Cancer
  323. Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status
  324. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells
  325. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
  326. Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series
  327. DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
  328. The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
  329. Deoxyribose Protects Against Rapamycin-Induced Cytotoxicity in Colorectal Cancer Cells In Vitro
  330. Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LCMSMS
  331. Gout and Hyperuricemia in Japan: Perspectives for International Research on Purines and Pyrimidines in Man
  332. Lipophilic Prodrugs and Formulations of Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
  333. Regulation of Deoxycytidine Kinase Expression and Sensitivity to Gemcitabine by Micro-RNA 330 and Promoter Methylation in Cancer Cells
  334. Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
  335. Association Between DNA-repair Polymorphisms and Survival in Pancreatic Cancer Patients Treated with Combination Chemotherapy
  336. TYMP (thymidine phosphorylase)
  337. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation
  338. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
  339. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
  340. Thymidylate synthase inhibitors for non-small cell lung cancer
  341. Towards Tailored Therapy of Glioblastoma Multiforme
  342. Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies
  343. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
  344. Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer
  345. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine
  346. Tolerability and Safety of Conventional Thiopurines Concomitantly With Allopurinol in IBD-Patients With a Skewed Thiopurine Metabolism
  347. Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
  348. Abstract 746: Acquired bortezomib resistance in non-small cell lung cancer is associated with overexpression of the mutated β5 proteasome subunit
  349. Abstract 2852: Lysosomal sequestration of sunitinib may play a role in its resistance
  350. Abstract 1941: TRAIL-induced kinase activation in Non small cell lung cancer cells
  351. Abstract 5041: Thymidylate synthase (TS) in malignant pleural mesothelioma (MPM): Correlation with clinical outcome and pharmacological role in the synergistic interaction of vandetanib with pemetrexed/carboplatin combination
  352. Discovery of N -Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells
  353. Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors
  354. Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients
  355. Impact of ABCG2 Polymorphisms on the Clinical Outcome and Toxicity of Gefitinib in Non-Small-Cell Lung Cancer Patients
  356. The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB
  357. Analysis of Drug Interactions
  358. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
  359. Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
  360. 46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?
  361. 189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers
  362. Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells
  363. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma
  364. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase
  365. Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin
  366. Limited Intra-Individual Variability in Hypoxanthine-Guanine Phosphoribosyl Transferase, Thiopurine S-Methyl Transferase, and Xanthine Oxidase Activity in Inflammatory Bowel Disease Patients During 6-Thioguanine Therapy
  367. Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells
  368. Increased Migration by Stimulation of Thymidine Phosphorylase in Endothelial Cells of Different Origin
  369. Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells
  370. Methylation Specific PCR to Characterize Methylation of the Promoter of Deoxycytidine Kinase
  371. Purine and Pyrimidine Metabolism in the Fist Decade of the 21st Century—Highlights and Perspectives
  372. The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues
  373. MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
  374. A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
  375. Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer
  376. Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing
  377. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
  378. Abstract 2146: DNA copy number profiles associated with clinical outcome in advanced colorectal cancer patients treated with folfiri and aliri regimens
  379. Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity
  380. Abstract 3000: MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma
  381. Abstract 1261: TRAIL-induced pro- and antiapoptotic kinase activation in non-small cell lung cancer cells
  382. Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
  383. Association of Polymorphisms inAKT1andEGFRwith Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib
  384. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
  385. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
  386. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5‐fluorouracil in colon cancer cells
  387. Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
  388. Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine
  389. Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
  390. Abstract B65: Overexpression of MRP4 or MRP5 confers resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
  391. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel
  392. On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
  393. Synthesis of 2‐Fluoro N10‐Substituted Acridones and Their Cytotoxicity Studies in Sensitive and Resistant Cancer Cell Lines and Their DNA Intercalation Studies
  394. OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib
  395. Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents
  396. SP154 The role of pharmacogenetics and pharmacogenomics in cancer therapy
  397. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion
  398. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
  399. Polymorphisms in the Enhancer Region of the Thymidylate Synthase Gene Are Associated with Thymidylate Synthase Levels in Normal Tissues but Not in Malignant Tissues of Patients with Colorectal Cancer
  400. Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines
  401. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer
  402. Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
  403. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
  404. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center
  405. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis
  406. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
  407. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia
  408. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins
  409. Intracellular Trafficking of MDR Transporters and Relevance of SNPs
  410. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
  411. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
  412. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
  413. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent
  414. Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
  415. Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
  416. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts
  417. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study
  418. Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples
  419. Functional Inactivity and Mutations of p53 Differentially Affect Sensitivity to 5-Fluorouracil and Antifolate Inhibitors of Thymidylate Synthase (TS) by Altering TS Levels in Colorectal Cancer Cells
  420. Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines, and NSCLC Patient Samples
  421. Selective Protection by Uridine of Growth Inhibition by 5-Fluorouracil (5FU) Mediated by 5FU Incorporation into RNA, But Not the Thymidylate Synthase Mediated Growth Inhibition by 5FU-Leucovorin
  422. The Role of Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Tumor Behavior
  423. Trifluorothymidine Induces Cell Death Independently of p53
  424. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco‐2 cells
  425. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines
  426. Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
  427. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo
  428. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
  429. Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
  430. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels
  431. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia
  432. In Vivo and in Vitro Activity And Mechanism Of Action of the Multidrug Cytarabine-L-Glycerylyl-Fluorodeoxyuridine
  433. Troxacitabine Prodrugs for Pancreatic Cancer
  434. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines
  435. O 6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor–induced resistance against temozolomide in human melanoma cells
  436. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds
  437. Mechanisms of action of FdUMP[10]: Metabolite activation and thymidylate synthase inhibition
  438. Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug
  439. A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
  440. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies
  441. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent
  442. Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung
  443. In vivo toxicological effects and spectral studies of organotin(IV) N‐maleoylglycinates M. I. Khan, Musa Kaleem Baloch, Muhammad Ashfaq and G. J. Peters Applied Organometallic Chemistry 2005; 19: 132
  444. In Vitro Optimization of Non-Small Cell Lung Cancer Activity with Troxacitabine, l-1,3-Dioxolane-cytidine, Prodrugs
  445. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5‐fluorouracil to patients with colorectal cancer
  446. Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule
  447. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
  448. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry
  449. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines
  450. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine
  451. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
  452. The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
  453. Thymidylate synthase inhibitors
  454. 614 POSTER Synergistic interaction between erlotinib and JM-118, the active metabolite of satraplatin
  455. Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by γ-irradiation
  456. Analysis of Deoxycytidine Accumulation in Gemcitabine Treated Patients
  457. Cellular Resistance Against Troxacitabine in Human Cell Lines and Pediatric Patient Acute Myeloid Leukemia Blast Cells
  458. Enhanced Activity of Deoxycytidine Kinase After Pulsed Low Dose Rate and Single Dose Gamma Irradiation
  459. Micro-Array Analysis of Resistance for Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunits
  460. Purine and Pyrimidine Metabolism: a Firm Basis for a Transformed Society
  461. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines
  462. Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer
  463. Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy
  464. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines
  465. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase
  466. The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells
  467. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment
  468. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
  469. Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations
  470. No evidence of gemcitabine accumulation during weekly administration
  471. In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
  472. Potentiation of in vitro ara‐C cytotoxicity by ribonucleotide reductase inhibitors, cyclin‐dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia
  473. Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures
  474. ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates
  475. Pyrimidine and Purine Analogues, Effects on Cell Cycle Regulation and the Role of Cell Cycle Inhibitors to Enhance Their Cytotoxicity
  476. Erratum for vol. 106, p. 717
  477. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia
  478. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells
  479. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours
  480. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
  481. Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs
  482. Pharmacokinetics of Bolus 5-Fluorouracil: Relationship Between Dose, Plasma Concentrations, Area-Under-the-Curve and Toxicity
  483. The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates
  484. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
  485. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells
  486. In vivo toxicological effects and spectral studies of organotin(IV)N-maleoylglycinates
  487. A Non‐Radioactive Sensitive Assay to Measure 5‐Fluorouracil Incorporation into DNA of Solid Tumors
  488. Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Arabinosylcytosine (ara‐C) in Leukemia and Solid Tumor Cell Lines
  489. Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts
  490. Combinations of 5‐Fluorouracil with UCN‐01 or Staurosporine
  491. Comparison of mRNA Expression Levels Determined with TAQ–Man and Competitive Template RT–PCR
  492. Immunocytochemical Detection of Deoxycytidine Kinase in Pediatric Malignancies in Relation to In Vitro Cytarabine Sensitivity
  493. Intracellular Thymidylate Synthase Inhibition by Trifluorothymidine in FM3A Cells
  494. Modulation of Cytarabine Induced Cytotoxicity Using Novel Deoxynucleoside Analogs in the HL60 Cell Line
  495. Online Fluorescent Method to Assess BCRP/ABCG2 Activity in Suspension Cells
  496. Polymorphism of the Thymidylate Synthase Gene and Thymidylate Synthase Levels in Colon Cancer Cell Lines and Different Tissues of Colorectal Cancer Patients
  497. Purine and Pyrimidine Metabolism: New Challenges
  498. Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cycler PCR; in Relation to Enzyme Activity
  499. Role of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyribose‐1‐Phosphate
  500. Upregulation of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase by Interferon Alpha
  501. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy
  502. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia
  503. Disparate Mechanisms of Antifolate Resistance Provoked by Methotrexate and Its Metabolite 7-Hydroxymethotrexate in Leukemia Cells: Implications for Efficacy of Methotrexate Therapy.
  504. Sensitivity and Cross-Resistance to Deoxynucleoside Analogs in Childhood Acute Leukemia.
  505. Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach
  506. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours
  507. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity
  508. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000
  509. Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells
  510. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers
  511. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil
  512. Erratum for vol. 103, p. 2908
  513. The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors
  514. Cancer of the esophagus and gastric cardia: recent advances*
  515. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
  516. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase
  517. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
  518. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1)
  519. 275: Intravesical Administration of Gemcitabine in Superficial Bladder Cancer: A Phase I Study with Pharmacodynamic Evaluation. A Phase II Study with Chemoresection of the Marker Lesion
  520. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer
  521. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation
  522. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines
  523. Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study
  524. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer
  525. Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia
  526. Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Pigs
  527. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods
  528. An Expedient Assay for Determination of Gemcitabine and Its Metabolite in Human Plasma Using Isocratic Ion-Pair Reversed-Phase High-Performance Liquid Chromatography
  529. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma
  530. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression
  531. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
  532. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines
  533. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
  534. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver
  535. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity
  536. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis
  537. Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells
  538. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells
  539. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines
  540. Thymidylate synthase inhibitors
  541. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia
  542. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines
  543. Effects of antifolates on the binding of 5-fluoro-2′-deoxyuridine monophosphate to thymidylate synthase
  544. 3′-Azido-2′,3′-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells
  545. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
  546. Erratum to “Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)”
  547. Gemcitabine–radiotherapy in patients with locally advanced pancreatic cancer
  548. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance
  549. Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors
  550. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases
  551. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
  552. Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside
  553. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
  554. High-Dose 5-Fluorouracil with Uridine-Diphosphoglucose Rescue Increases Thymidylate Synthase Inhibition but Not 5-Fluorouracil Incorporation into RNA in Murine Tumors
  555. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis
  556. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin
  557. Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR
  558. Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor
  559. Folate homeostasis and antiproliferative activity of folates and antifolates
  560. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
  561. Chemotherapeutic Strategies for Treatment of Colorectal Cancer: Present and Future Developments
  562. Simultaneous determination of F-β-alanine and β-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography
  563. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay
  564. Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines11Abbreviations: ara-C,1-β-d-arabinofuranosylcytosine; dCDA, deoxycytid...
  565. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer
  566. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox
  567. Differences in the Induction of DNA Damage, Cell Cycle Arrest, and Cell Death by 5-Fluorouracil and Antifolates
  568. Synthesis and in vitro cytotoxicity of novel long chain busulphan analogues
  569. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia
  570. Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells
  571. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients
  572. Issues of Normal Tissue Toxicity in Patient and Animal Studies - Effect of Carbogen Breathing in Rats after 5-Fluorouracil Treatment
  573. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method
  574. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours
  575. The multilayered postconfluent cell culture as a model for drug screening
  576. The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells
  577. Clustering of Mutations in the First Transmembrane Domain of the Human Reduced Folate Carrier in GW1843U89-resistant Leukemia Cells with Impaired Antifolate Transport and Augmented Folate Uptake
  578. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs
  579. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
  580. Classification Of Ex Vivo Methotrexate Resistance In Acute Lymphoblastic and Myeloid Leukaemia
  581. L-Dopa stimulates expression of the antioxidant enzyme NAD(P)H:quinone oxidoreductase (NQO) in cultured astroglial cells
  582. Basis for effective combination cancer chemotherapy with antimetabolites
  583. Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors
  584. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia
  585. Thymidylate Synthase Expression in Patients with Colorectal Carcinoma Using a Polyclonal Thymidylate Synthase Antibody in Comparison to the TS 106 Monoclonal Antibody
  586. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed
  587. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors
  588. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines
  589. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates
  590. Gemcitabine–cisplatin: A schedule finding study
  591. Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo
  592. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan–5-fluorouracil combination in human colon carcinoma cell lines
  593. 5-Ethyl-2′-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil
  594. Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates
  595. Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates
  596. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs
  597. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
  598. Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung Cancer
  599. MRP3, an organic anion transporter able to transport anti-cancer drugs
  600. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures
  601. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
  602. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
  603. Continuous Exposure to Methotrexate (MTX) Overcomes Resistance in Childhood Acute Myeloid Leukemia (AML) in Vitro
  604. Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice
  605. Biological Activity of 1-Deazapurine Nucleosides: Role of Deoxycytidine Kinase?
  606. Cell Specific Cytotoxicity and Structure-Activity Relationship of Lipophilic 1-B-D-Arabinofuranosylcytosine (Ara-C) Derivatives
  607. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
  608. Synthesis, in vitro cytotoxicity and in vivo anti-inflammatory activity of long chain 3-amino-1,2-diols
  609. Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia
  610. Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia
  611. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines
  612. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase
  613. Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay
  614. Experimental drugs and drug combinations in pancreatic cancer
  615. Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal Cancer
  616. A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance
  617. Augmentation of 1-β-d-Arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs
  618. Postconfluent multilayered cell line cultures for selective screening of gemcitabine
  619. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML
  620. Erratum: J Cancer Res Clin Oncol (1997) 123: 595—601
  621. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer
  622. Cross-Resistance of the Gemcitabine Resistant Human Ovarian Cancer Cell Line AG6000 to Standard and Investigational Drugs
  623. Determinants of the Therapeutic Efficacy of Thymidylate Synthase Inhibitors
  624. Differential Effects of Gemcitabine on Nucleotide Pools of 19 Solid Tumor Cell Lines
  625. Dihydropyrimidine Dehydrogenase in Livers from Mouse and Rat, and in Human Liver, Colon Tumors, and Mucosa in Relation to Anabolism of 5-Fluorouracil
  626. Increased Sensitivity to Gemcitabine of P-gP and MRP Overexpressing Human Non-Small Cell Lung Cancer Cell Lines
  627. Induction of in Vivo Resistance Against Gemcitabine (dFdC,2′,2′-Difluoro-Deoxycytidine)
  628. Mechanisms of Synergism Between Gemcitabine and Cisplatin
  629. No Circadian Variation of Dihydropyrimidine Dehydrogenase, Uridine Phosphorylase, β-Alanine, and 5-Fluorouracil During Continuous Infusion of 5-Fluorouracil
  630. Role of Deoxycytidine Kinase (dCK), Thymidine Kinase 2 (TK2), and Deoxycytidine Deaminase (dCDA) in the Antitumor Activity of Gemcitabine (dFdC)
  631. Similar Changes Were Induced by Cladribine and by Gemcitabine, in the Deoxypyrimidine Salvage, During Short Term Treatments
  632. The Role of Thymidine Kinase Activity in Murine Colon Tumours Treated with 5-Fluorouracil
  633. Toxicity Profiles In Vivo in Mice and Antitumour Activity inTumour‐Bearing Mice of Di‐ and Triorganotin Compounds
  634. 5-Fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man
  635. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression
  636. Gemcitabine: Future Prospects of Single-Agent and Combination Studies
  637. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells
  638. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells
  639. The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics
  640. Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas
  641. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors
  642. Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development
  643. In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of four diorganotin compounds
  644. 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two Colon tumors with a different 5-fluorouracil sensitivity: A study for a correlation with oncological results
  645. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9
  646. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine
  647. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-l-aspartate in human leukemic blast cells and cell lines
  648. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts
  649. The combination 5‐fluorouracil/levamisole induces enhanced rat kupffer cell‐mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531
  650. Thymidylate synthase as a target in cancer chemotherapy
  651. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
  652. Quantification of 5-Fluorouracil Incorporation into RNA of Human and Murine Tumors as Measured with a Sensitive Gas Chromatography-Mass Spectrometry Assay
  653. Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice
  654. Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: Relationship between plasma concentrations and clinical parameters
  655. Preface
  656. Thymidylate synthase and drug resistance
  657. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-l-aspartate in murine colon carcinoma no. 26
  658. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: Potentiating or reversing effect?
  659. Three-Dimensional Cell Cultures as a Model System to Evaluate the Biological Activity of Gemcitabine (2', 2'-Difluoro-2'deoxycytidine)
  660. Comparison of 5-Fluoro-2’-Deoxyuridine and 5-Fluorouracil in the Treatment of Murine Colon Cancer; Effects on Thymidylate Synthase
  661. Cross-Resistance to Thymidylate Synthase Inhibitors in P-Glycoprotein and Non-P-Glycoprotein Cell Lines
  662. Protection of Normal Tissues from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine (WR-2721): Preclinical Aspects
  663. Purine Nucleotide Interconversion Enzymes in Childhood Leukemia: Relation with Cell Cycle and Clinical Outcome
  664. Synergistic Interaction between Cisplatin and Gemcitabine in Ovarian and Colon Cancer Cell Lines
  665. The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat
  666. Therapy Related Disturbances in Nucleotides in Cancer Cells
  667. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
  668. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.
  669. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures
  670. New targets for pyrimidine antimetabolites in the treatment of solid tumours
  671. New targets for pyrimidine antimetabolites in the treatment of solid tumours
  672. Purine and pyrimidine metabolism: still a black box?
  673. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression
  674. New targets for pyrimidine antimetabolites for the treatment of solid tumours
  675. New targets for pyrimidine antimetabolites in the treatment of solid tumours
  676. Purine and pyrimidine metabolism: still a black box?
  677. IN-VITRO SCHEDULE-DEPENDENCY OF EO9 AND MILTEFOSINE IN COMPARISON TO STANDARD DRUGS IN COLON-CANCER CELLS
  678. Antimetabolite-induced increases in the invasive capacity of murine leukaemia L1210 cells
  679. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate
  680. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
  681. In vitro sequence-dependent synergistic effect of suramin and camptothecin
  682. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase
  683. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin
  684. Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma
  685. In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis
  686. Determination of the Antimetabolite Gemcitabine (2′,2′-Difluoro-2′-deoxycytidine) and of 2′,2′-Difluoro-2′-deoxyuridine by 19F Nuclear Magnetic Resonance Spectroscopy
  687. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
  688. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma
  689. Transformation of mouse fibroblasts with the oncogenes H‐ras or trk is associated with pronounced changes in drug sensitivity and metabolism
  690. Novel approaches to selective treatments of human solid tumors: Laboratory and clinical correlation
  691. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine
  692. Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'- monophosphate to thymidylate synthase
  693. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts
  694. The Interval Between Methotrexate and Leucovorin Determines the Efficacy of 5-Fluorouracil Modulation in Vitro and in Vivo
  695. Variable Pharmacodynamics of Antifolates in Squamous Cell Carcinoma of the Head and Neck
  696. Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine
  697. Changes in glycosylation of L1210 cells after exposure to various antimetabolites
  698. Comparison of Continuous Infusions and Bolus Injections of 5.Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase
  699. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures
  700. Development of a Simple Folylpolyglutamate Synthetase Assay in Tissues and Cell Lines
  701. Evaluation of Immunohistochemical Staining and Activity of Thymidylate Synthase in Cell Lines
  702. Potentiation of 5-Fluorouracil Induced Inhibition of Thymidylate Synthase in Human Colon Tumors by Leucovorin is Dose Dependent
  703. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates
  704. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia
  705. The effect of schedule, protein binding and growth factors on the activity of suramin
  706. Hypoxanthine‐guanine phosphoribosyl‐transferase in childhood leukemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosis
  707. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil
  708. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine
  709. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice
  710. Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil
  711. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa
  712. Expression of 5'-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage
  713. Expression of 5'-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage
  714. Clinical relevance of biochemical modulation of 5-fluorouracil
  715. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing
  716. Clinical and Pharmacologic Study of Orally Administrated Uridine
  717. In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides
  718. Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system
  719. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: Enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate
  720. Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose
  721. Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?
  722. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squanmous cell carcinoma xenografts
  723. Retention of in vivo antipyrimidine effects of brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer
  724. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by Brequinar Sodium
  725. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma
  726. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes
  727. Reversal of 5-Fluorouracil-Induced Myelosuppression by Prolonged Administration of High-Dose Uridine
  728. Fluoropyrimidine Metabolism in Human Head and Neck Cancer Xenografts and Murine Colon Tumors
  729. In Vitro and In Vivo Inhibition of Thymidylate Synthase of Human Colon Cancer by 5-Fluorouracil
  730. Incorporation of 5-Fluorouracil into Nucleotide Sugars and the Effect on Glycoconjugates in Rat Hepatoma Cells and Hepatocytes
  731. Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer
  732. The Relationship between Dihydroorotic Acid Dehydrogenase and In Vitro and In Vivo Cytostatic Effects of Brequinar Sodium (DUP-785; NSC 368390)
  733. A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography
  734. Fluorouracil: biochemistry and pharmacology.
  735. DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effects
  736. 114 FLUOROPYRIMIDINE METABOLISM IN HUMAN HEAD AND NECK CANCER XENOGRAFTS AND MURINE COLON TUMORS
  737. 125 INCORPORATION OF 5-FLUOROURACIL INTO NUCLEOTIDE SUGARS AND THE EFFECT ON GLYCOCONJUGATES IN RAT HEPATOMA CELLS AND HEPATOCYTES
  738. Uridine induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites
  739. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil
  740. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites
  741. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity
  742. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites
  743. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
  744. A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography
  745. Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities
  746. Modulation of Cytotoxicity and Metabolism of 5-Fluorouracil in two Intestine Cell Lines
  747. Toxicity and Antitumor Effect of 5-Fluorouracil and its Rescue by Uridine
  748. MODULATION OF CYTOTOXICITY AND METABOLISM OF 5-FLUOROURACIL (FU) IN TWO INTESTINE CELL LINES: 156
  749. Discrepancies in ribonucleotide concentrations in human lymphocytes isolated from heparinized and defibrinized blood
  750. Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry
  751. The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites
  752. Separation of several 5-Fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-Fluorouracil-nucleotide sugars
  753. Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines
  754. Concentration of Nucleotides in Peripheral Blood Lymphocytes of Various Mammalian Species
  755. Metabolism of Guanosine and Deoxyguanosine in Mammalian Lymphocytes and their Influence on Mitogenic Stimulation
  756. Purine Metabolism in Splenocytes and Thymocytes of Various Mammalian Species
  757. Pyrimidine Metabolism in Rat Brain Cortex and Liver
  758. Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high-performance liquid chromatography on a column with porous polymeric packing
  759. Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes
  760. Metabolism of purine nucleosides in human and ovine lymphocytes and rat thymocytes and their influence on mitogenic stimulation
  761. Purine and pyrimidine metabolism in peripheral blood lymphocytes
  762. Pyrimidine metabolism in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes
  763. Stimulation by phytohaemagglutinin of peripheral blood lymphocytes from horse, pig, sheep and man
  764. Age-Dependency of Adenosine Deaminase and Purine Nucleoside Phosphorylase Activities in Rat Spleen and Thymus
  765. Effects of adenosine and deoxyadenosine on pha-stimulation of lymphocytes of man, horse and pig
  766. Metabolism of purine nucleosides and phosphoribosylpyrophosphate in thymocytes and splenocytes of various mammalian species
  767. Adenosine and deoxyadenosine metabolism in mammalian lymphocytes
  768. Metabolism of phosphoribosylpyrophosphate in peripheral and phytohemagglutin-stimulated mammalian lymphocytes
  769. Concentration, synthesis and utilization of phosphoribosylpyrophosphate in lymphocytes of five mammalian species
  770. Pyrimidine metabolism in lymphocytes and erythrocytes of man, horse and cattle